Who: Mammoth Biosciences, Inc. ; Vertex Pharmaceuticals Incorporated
What: Vertex and Mammoth are partnering to develop in vivo gene-editing therapies for two serious diseases, using Mammoth’s CRISPR technology.
Vertex Gains In Vivo CRISPR Foothold With Mammoth Pact
Listen to this article
Deal Snapshot: The nearly $700m deal gives Vertex, already with a major foothold in CRISPR, access to Mammoth’s ultra-compact gene-editing technology in two diseases.
Keep up with the top pharma business news of the week. On the go.
More from Archive
Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.
• By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
• By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
• By
GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains